» Articles » PMID: 39542958

Lacrimal Gland Enlargement in Thyroid Eye Disease

Overview
Journal Int Ophthalmol
Specialty Ophthalmology
Date 2024 Nov 14
PMID 39542958
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: This study aimed to investigate lacrimal gland (LG) enlargement in thyroid eye disease (TED) patients on magnetic resonance imaging (MRI).

Methods: A retrospective review was conducted on TED patients who had undergone fat-suppressed contrast-enhanced T1-weighted MRI of the orbits. The lacrimal gland was segmented on OsiriX in consecutive axial and coronal slices to determine its volume. Enlargement was defined as a volume greater than 1100mm, based on previous normative data. Asymmetric enlargement was defined if one side was enlarged but the contralateral side was not. Clinical data including presentation (active/inactive) and presence or absence of dysthyroid optic neuropathy was evaluated.

Results: The study population consisted of 88 orbits from forty-four patients with a mean age of 53 ± 15 years, with 29 (65%) being female. Twelve patients (27%) had LG enlargement, with eight (18%) having bilateral enlargement and four (9%) having asymmetric enlargement. There was no significant difference in age (p = 0.17) or sex (p = 0.44) between the LG enlarged and non-enlarged groups. There was also no significant difference in the clinical activity (p = 0.46) or prevalence of dysthyroid optic neuropathy (p = 0.63) between the LG enlarged orbits and non-LG enlarged orbits.

Conclusion: Lacrimal gland enlargement may be observed in approximately thirty percent of TED patients, with asymmetric enlargement in approximately ten percent of cases.

References
1.
Bingham C, Harris M, Realini T, Nguyen J, Hogg J, Sivak-Callcott J . Calculated computed tomography volumes of lacrimal glands and comparison to clinical findings in patients with thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2014; 30(2):116-8. DOI: 10.1097/IOP.0000000000000015. View

2.
Huang D, Luo Q, Yang H, Mao Y . Changes of lacrimal gland and tear inflammatory cytokines in thyroid-associated ophthalmopathy. Invest Ophthalmol Vis Sci. 2014; 55(8):4935-43. DOI: 10.1167/iovs.13-13704. View

3.
Bartley G, Fatourechi V, Kadrmas E, Jacobsen S, Ilstrup D, Garrity J . Clinical features of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996; 121(3):284-90. DOI: 10.1016/s0002-9394(14)70276-4. View

4.
McKeag D, Lane C, Lazarus J, Baldeschi L, Boboridis K, Dickinson A . Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey. Br J Ophthalmol. 2006; 91(4):455-8. PMC: 1994756. DOI: 10.1136/bjo.2006.094607. View

5.
Rana K, Garg D, Patel S, Selva D . Imaging of dysthyroid optic neuropathy. Eur J Ophthalmol. 2023; 34(5):1346-1354. DOI: 10.1177/11206721231199367. View